Cellular oncogenes are believed to play a role in normal cell proliferation and/or differentiation. In addition evidence exists linking adherent expression of these genes to malignant transformation. We have demonstrated that the cellular oncogenes: c-abl, c-erb, c-fos, c-myc, c-ras?Ha?, c-src, and c-sis are all expressed during murine embryogenesis. Five of these genes; c-abl, c-fos, c-myc, c-ras?Ha? and c-src were expressed in a time related and/or tissue specific fashion during embryogenesis. The expression of cellular oncogenes was determined by analysis of mRNA obtained from whole mouse embryos at various stages of development. This approach does not identify the specific tissues responsible for the bulk of expression of a given cellular oncogene. For this reason we are developing histochemical techniques to clarify the issue. We are also studied cellular oncogene expression in a large survey of 53 human malignancies representing 20 different tumor types and found expression of c-fos, c-myc, c-ras?Ha? and c-ras?Ki? in all tumors. The c-abl, c-fes, c-fms and c-myb genes were expressed in certain tumors. Given the strong association of the c-myb oncogene with human leukemia we obtained a c-DNA clone of this gene from fresh human leukemic blasts and expressed this clone in a bacterial expression. The expressed fusion protein was used as an immunogen to develop specific anti-myb antisera. A similar approach was taken with the c-fos gene product and given us specific antisera for this product. (X)

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA036827-02
Application #
3174404
Study Section
Pathology B Study Section (PTHB)
Project Start
1984-07-01
Project End
1987-06-30
Budget Start
1985-07-01
Budget End
1986-06-30
Support Year
2
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Wilson, C A; Ramos, L; Villasenor, M R et al. (1999) Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet 21:236-40
Pietras, R J; Poen, J C; Gallardo, D et al. (1999) Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 59:1347-55
Pietras, R J; Pegram, M D; Finn, R S et al. (1998) Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17:2235-49
Pegram, M D; Finn, R S; Arzoo, K et al. (1997) The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15:537-47
Reese, D M; Slamon, D J (1997) HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells 15:1-8
Wilson, C A; Payton, M N; Elliott, G S et al. (1997) Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b. Oncogene 14:1-16
Pauletti, G; Godolphin, W; Press, M F et al. (1996) Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13:63-72
Pisani, A L; Barbuto, D A; Chen, D et al. (1995) HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma. Obstet Gynecol 85:729-34
Silverstein, M J; Poller, D N; Waisman, J R et al. (1995) Prognostic classification of breast ductal carcinoma-in-situ. Lancet 345:1154-7
Pietras, R J; Arboleda, J; Reese, D M et al. (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435-46

Showing the most recent 10 out of 29 publications